I'm not surprised to see the company trading at a 5 year low. Post-COVID demand has slowed and higher interest rates have really impacted funding for pharma companies.
However, the company is still a very strong cash flow generator with a strong margin profile and a rock-solid balance sheet. I think it's fairly beat up here due to the negative sentiment overall with pharma/biotech companies.
It's not something I would personally own as I have just avoided the space entirely but on the basis of whether or not its a solid company, it definitely is.